Andersen MR, Goff BA, Lowe KA, et al.

Combining a symptoms index with CA 125 to improve

detection of ovarian cancer. Cancer 2008; 113:484.
Andersen MR, Goff BA, Lowe KA, et al. Use of a Symptom Index, CA125, and HE4 to predict ovarian
cancer. Gynecol Oncol 2010; 116:378.
Anderson GL, McIntosh M, Wu L, et al. Assessing lead time of selected ovarian cancer biomarkers: a
nested case-control study. J Natl Cancer Inst 2010; 102:26.
Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with
BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined
analysis of 22 studies. Am J Hum Genet 2003; 72:1117.
Barnholtz-Sloan JS, Schwartz AG, Qureshi F, et al. Ovarian cancer: changes in patterns at diagnosis and
relative survival over the last three decades. Am J Obstet Gynecol 2003; 189:1120.
Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch
syndrome: a report of 121 families with proven mutations. Clin Genet 2009; 75:141.
Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the
course of epithelial ovarian cancer. N Engl J Med 1983; 309:883.
Bloomfield HE, Olson A, Greer N, et al. Screening pelvic examinations in asymptomatic, average-risk
adult women: an evidence report for a clinical practice guideline from the American College of
Physicians. Ann Intern Med 2014; 161:46.

Bourne TH, Campbell S, Reynolds KM, et al. Screening for early familial ovarian cancer with
transvaginal ultrasonography and colour blood flow imaging. BMJ 1993; 306:1025.
Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk after the use of ovulation-stimulating
drugs. Obstet Gynecol 2004; 103:1194.
Bristow RE, Karlan BY. Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril 1996;
66:499.
Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung,
Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;
305:2295.
Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and
Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am
J Obstet Gynecol 2005; 193:1630.
Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive care.
Canada Communication Group, Ottawa 1994. p.869. Available at: www.ctfphc.org/ (Accessed on
August 24, 2009).
Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med 1994; 121:124.
Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009; 361:170.
Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian
cancer. Cancer 1996; 77:2318.

Daly M, Obrams GI. Epidemiology and risk assessment for ovarian cancer. Semin Oncol 1998; 25:255.
Devarbhavi H, Kaese D, Williams AW, et al. Cancer antigen 125 in patients with chronic liver disease.
Mayo Clin Proc 2002; 77:538.
Einhorn N, Sjvall K, Knapp RC, et al. Prospective evaluation of serum CA 125 levels for early
detection of ovarian cancer. Obstet Gynecol 1992; 80:14.
Fishman DA, Cohen L, Blank SV, et al. The role of ultrasound evaluation in the detection of early-stage
epithelial ovarian cancer. Am J Obstet Gynecol 2005; 192:1214.
Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE. Frequency of BRCA1 dysfunction in ovarian
cancer. J Natl Cancer Inst 2002; 94:61.
Havrilesky LJ, Sanders GD, Kulasingam S, Myers ER. Reducing ovarian cancer mortality through
screening: Is it possible, and can we afford it? Gynecol Oncol 2008; 111:179.
Hermsen BB, Olivier RI, Verheijen RH, et al. No efficacy of annual gynaecological screening in
BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007; 96:1335.
Hilton JL, Geisler JP, Rathe JA, et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl
Cancer Inst 2002; 94:1396.
http://campaign.r20.constantcontact.com.sci-hub.cc/render?llr=65mauybab&v=001VufbrhO4aadFDnJTbyN09ViVj3jkTJ_HTKrI7tz4ROKSpiyEdS8IGdXFEWGWQCY9P3rldvwI
Ujj69wtTwvLNDziaynNC5j3fjEZYsWaLXEi5_syyBpqY3ALvetmf4TafTwtPXvlWt3aujdXjtyO
bZ_UfeVI3dk0JQ5hkJncIfXWMoM8PIAs8i-

7hecEYOz7AVz4Y6AxTvLx5EpckmDwGGtFHF9ZqZBqNaaSiq7oat (Accessed on September

25, 2012).
http://www.acog.org.secure.scihub.cc/Resources_And_Publications/Committee_Opinions/Committee_on_Gynecologic_Practic
e/The_Role_of_the_Obstetrician_Gynecologist_in_the_Early_Detection_of_Epithelial_Ovarian_
Cancer (Accessed on February 20, 2014).
http://www.uspreventiveservicestaskforce.org.sci-hub.cc/uspstf12/ovarian/ovarartaddend.htm (Accessed
on June 26, 2012).
Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women
by CA 125 measurement and ultrasonography. BMJ 1993; 306:1030.
Jacobs I. Genetic, biochemical, and multimodal approaches to screening for ovarian cancer. Gynecol
Oncol 1994; 55:S22.
Jacobs IJ, Skates S, Davies AP, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125
concentration: a prospective cohort study. BMJ 1996; 313:1355.
Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled
trial. Lancet 1999; 353:1207.
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet 2014; 384:1376.
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.

Johnson CC, Kessel B, Riley TL, et al. The epidemiology of CA-125 in women without evidence of
ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.
Gynecol Oncol 2008; 110:383.
Karlan BY, Raffel LJ, Crvenkovic G, et al. A multidisciplinary approach to the early detection of ovarian
carcinoma: rationale, protocol design, and early results. Am J Obstet Gynecol 1993; 169:494.
Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic
oophorectomy? Obstet Gynecol 1992; 80:700.
Khoury-Collado F, Bombard AT. Hereditary breast and ovarian cancer: what the primary care physician
should know. Obstet Gynecol Surv 2004; 59:537.
Kobayashi H, Yamada Y, Sado T, et al. A randomized study of screening for ovarian cancer: a
multicenter study in Japan. Int J Gynecol Cancer 2008; 18:414.
Kurman RJ, Visvanathan K, Roden R, et al. Early detection and treatment of ovarian cancer: shifting
from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J
Obstet Gynecol 2008; 198:351.
Lacey JV Jr, Greene MH, Buys SS, et al. Ovarian cancer screening in women with a family history of
breast or ovarian cancer. Obstet Gynecol 2006; 108:1176.
Lynch HT, Bewtra C, Lynch JF. Familial ovarian carcinoma. Clinical nuances. Am J Med 1986;
81:1073.

Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound
screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence
screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol
2009; 10:327.
Menon U, Skates SJ, Lewis S, et al. Prospective study using the risk of ovarian cancer algorithm to
screen for ovarian cancer. J Clin Oncol 2005; 23:7919.
Mol BW, Bayram N, Lijmer JG, et al. The performance of CA-125 measurement in the detection of
endometriosis: a meta-analysis. Fertil Steril 1998; 70:1101.
Moore LE, Pfeiffer RM, Zhang Z, et al. Proteomic biomarkers in combination with CA 125 for detection
of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung,
Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer 2012; 118:91.
Moore RG, MacLaughlan S, Bast RC Jr. Current state of biomarker development for clinical application
in epithelial ovarian cancer. Gynecol Oncol 2010; 116:240.
Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and
CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;
112:40.
Moyer VA, U.S. Preventive Services Task Force. Screening for ovarian cancer: U.S. Preventive Services
Task Force reaffirmation recommendation statement. Ann Intern Med 2012; 157:900.

National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology.
http://www.nccn.org.sci-hub.cc/professionals/physician_gls/f_guidelines.asp (Accessed on
February 27, 2016).
Nelson AE, Francis JE, Zorbas H, National Breast and Ovarian Cancer Centre. Population screening and
early detection of ovarian cancer in asymptomatic women. Aust N Z J Obstet Gynaecol 2009;
49:448.
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS): a randomised controlled trial. Lancet 2015.
Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a
randomized trial. Obstet Gynecol 2009; 113:775.
Pavlik EJ, DePriest PD, Gallion HH, et al. Ovarian volume related to age. Gynecol Oncol 2000; 77:410.
Pickhardt PJ, Hanson ME. Incidental adnexal masses detected at low-dose unenhanced CT in
asymptomatic women age 50 and older: implications for clinical management and ovarian cancer
screening. Radiology 2010; 257:144.
Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian
(PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21:273S.
Rosenthal AN, Fraser L, Manchanda R, et al. Results of annual screening in phase I of the United
Kingdom familial ovarian cancer screening study highlight the need for strict adherence to
screening schedule. J Clin Oncol 2013; 31:49.

Rosenthal AN, Menon U, Jacobs IJ. Screening for ovarian cancer. Clin Obstet Gynecol 2006; 49:433.
Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. Predictive value of symptoms for early
detection of ovarian cancer. J Natl Cancer Inst 2010; 102:222.
Rubin SC, Blackwood MA, Bandera C, et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal
cancer gene mutations in an unselected ovarian cancer population: relationship to family history
and implications for genetic testing. Am J Obstet Gynecol 1998; 178:670.
Schorge JO, Modesitt SC, Coleman RL, et al. SGO White Paper on ovarian cancer: etiology, screening
and surveillance. Gynecol Oncol 2010; 119:7.
Shah CA, Lowe KA, Paley P, et al. Influence of ovarian cancer risk status on the diagnostic performance
of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev
2009; 18:1365.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9.
Sjvall K, Nilsson B, Einhorn N. The significance of serum CA 125 elevation in malignant and
nonmalignant diseases. Gynecol Oncol 2002; 85:175.
Skates SJ, Menon U, MacDonald N, et al. Calculation of the risk of ovarian cancer from serial CA-125
values for preclinical detection in postmenopausal women. J Clin Oncol 2003; 21:206s.
Smith LH, Oi RH. Detection of malignant ovarian neoplasms: a review of the literature. III.
Immunological detection and ovarian cancer-associated antigens. Obstet Gynecol Surv 1984;
39:346.

Smith SA, Richards WE, Caito K, et al. BRCA1 germline mutations and polymorphisms in a clinicbased series of ovarian cancer cases: a Gynecologic Oncology Group study. Gynecol Oncol
2001; 83:586.
Stratton JF, Gayther SA, Russell P, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J
Med 1997; 336:1125.
The Surveillance Program, Division of Cancer Prevention and Control. Cancer Statistics Review 1973;
87, Publication no. 90-2789. National Cancer Institute, Washington, DC 1988.
Tobacman JK, Greene MH, Tucker MA, et al. Intra-abdominal carcinomatosis after prophylactic
oophorectomy in ovarian-cancer-prone families. Lancet 1982; 2:795.
Topalak O, Saygili U, Soyturk M, et al. Serum, pleural effusion, and ascites CA-125 levels in ovarian
cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol
2002; 85:108.
Urban N, Drescher C, Etzioni R, Colby C. Use of a stochastic simulation model to identify an efficient
protocol for ovarian cancer screening. Control Clin Trials 1997; 18:251.
Urban N, Hawley S, Janes H, et al. Identifying post-menopausal women at elevated risk for epithelial
ovarian cancer. Gynecol Oncol 2015; 139:253.
van Nagell JR Jr, Miller RW, DeSimone CP, et al. Long-term survival of women with epithelial ovarian
cancer detected by ultrasonographic screening. Obstet Gynecol 2011; 118:1212.

Weitzel JN, Lagos VI, Cullinane CA, et al. Limited family structure and BRCA gene mutation status in
single cases of breast cancer. JAMA 2007; 297:2587.
www.acog.org/from_home/publicationspress_releases/nr03-20-09.cfm (Accessed on August 24, 2009).
www.ahrq/gov/clinic/3rduspstf/ovariancan/ovcanrs.htm (Accessed on August 24, 2009).
www.cancer.gov/cancertopics/pdq/screening/ovarian/healthprofessional/allpages (Accessed on August
24, 2009).
Yurkovetsky Z, Skates S, Lomakin A, et al. Development of a multimarker assay for early detection of
ovarian cancer. J Clin Oncol 2010; 28:2159.
Zuckerman E, Lanir A, Sabo E, et al. Cancer antigen 125: a sensitive marker of ascites in patients with
liver cirrhosis. Am J Gastroenterol 1999; 94:1613.
Zurawski VR Jr, Orjaseter H, Andersen A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of
ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 1988; 42:677.